Finance

Lists
CMPX:NASDAQ
Compass Therapeutics Inc.
$0.69
+1.43%
(+0.0097) 1D
$0.67
-2.27% (-0.016)
After hours
Closed: Nov 20, 4:00:02 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CMPX...
Open
$0.67
High
$0.73
Low
$0.64
Mkt. cap
123.66M
Avg. vol.
2.40M
Volume
1.82M
52-wk high
$6.88
52-wk low
$0.57
EPS
-$0.46
Beta
1.06
Shares outstanding
180.09M
No. of employees
39
Open
$0.67
High
$0.73
Low
$0.64
Mkt. cap
123.66M
Avg. vol.
2.40M
Volume
1.82M
52-wk high
$6.88
52-wk low
$0.57
EPS
-$0.46
Beta
1.06
Shares outstanding
180.09M
No. of employees
39
News stories
From web sources and news partners
About Compass Therapeutics Inc.
CEO-
Employees39
Founded2014
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 10 analysts giving stock ratings to CMPX in the past 3 months
Strong buy
Buy
8
Hold
2
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for CMPX in the last 3 months.
Highest
Current $0.69
$12.00 (+1,643.68%)
Average
$6.00 (+771.84%)
Lowest
$1.00 (+45.31%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Schmidt
Guggenheim
Buy
Maintained
$4.00
+481.2%
11/09/2026
Stephen Willey
Stifel Nicolaus
Buy
Reiterated
$6.00
+771.8%
11/10/2026
John Newman
Canaccord Genuity
Buy
Maintained
$7.00
+917.1%
11/10/2026
Joseph Pantginis
H.C. Wainwright
Buy
Maintained
$12.00
+1,643.7%
11/09/2026
Biren Amin
Piper Sandler
Buy
Maintained
$6.00
+771.8%
10/26/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
10/26/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
$8.00
+1,062.5%
09/23/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
$4.00
+481.2%
09/23/2026
Robert Driscoll
Wedbush
Hold
Downgraded
$1.00
+45.3%
09/23/2026
Charles Zhu
LifeSci Capital
Hold
Downgraded
-
-
09/22/2026
Andrew Berens
Leerink Partners
Buy
Maintained
$7.00
+917.1%
08/07/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$8.00
+1,062.5%
05/06/2026
Sean McCutcheon
Raymond James
Hold
Downgraded
-
-
04/28/2026
Maury Raycroft
Jefferies
Buy
Maintained
$9.00
+1,207.8%
04/27/2026
Jonathan Chang
Leerink Partners
Buy
Maintained
$11.00
+1,498.4%
04/27/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$8.00
+1,062.5%
03/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
13.67M
13.39M
19.58M
22.04M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.32M
6.91M
7.40M
6.76M
Operating expense
17.99M
20.30M
26.98M
28.80M
Total operating expenses
17.99M
20.30M
26.98M
28.80M
Operating income
-17.99M
-20.30M
-26.98M
-28.80M
Other non operating income
-
-
-
-
EBT including unusual items
-15.72M
-18.32M
-25.15M
-27.17M
EBT excluding unusual items
-15.72M
-18.32M
-25.15M
-27.17M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15.72M
-18.32M
-25.15M
-27.17M
Net profit margin
-
-
-
-
Earnings per share
-0.09
-0.10
-0.13
-0.15
Interest and investment income
2.27M
1.98M
1.82M
1.63M
Interest expense
-
-
-
-
Net interest expenses
2.27M
1.98M
1.82M
1.63M
Depreciation and amortization charges
-
-
-
-
EBITDA
-17.97M
-20.28M
-26.96M
-28.77M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps